Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The economic costs of antimicrobial resistance (AMR) for every course of antibiotics are considerable, and much higher than their purchase cost, say researchers.

Study details high hidden economic costs of antibiotic consumption.png

In a landmark study, a team of researchers led by the Mahidol Oxford Research Centre (MORU) and the Infectious Diseases Data Observatory (IDDO) used data from the USA and Thailand to link the consumption of antibiotics with the direct and indirect costs of treating patients for five drug-resistant bacterial infections.

In a first, the experts looked at the consequences of antibiotic treatment failure –  higher death rates, lost earnings, more expensive diagnostics, costs to care providers and health systems – to calculate in USD the cost of antimicrobial resistance (AMR) for five types of antibiotic drugs widely used in the USA, a high-income country (HIC),  and in Thailand, a lower-middle income country (LMIC).

Find out more (IDDO website)